Expanding Transplant Access to Diverse Populations Using Mismatched Unrelated Donor (MMUD) Therapies

Disparities in access to fully matched unrelated donors for all patients in need persist despite a world-wide registry of over 39 million donors. Novel approaches to transplant that allow for the safe and effective use of mismatched donors hold the promise to close this gap and ensure a donor is available for all in need. This session will describe how recent research with mismatched unrelated donor (MMUD) therapies aims to expand access to transplant across diverse patient populations. The 15-MMUD, ACCESS, ABA2 and ABA3 clinical trials will be discussed, and well as the future of MMUD therapies and how these therapies will expand access to care.


  • Antonio Jimenez Jimenez, MD, MSc, Assistant Professor of Medicine, University of Miami, Sylvester Comprehensive Cancer Center
  • Muna Qayed, MD, MsCR, Director, Blood and Marrow Transplantation Program, Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta and Emory University
  • Stephen Spellman, MBS, Vice President, Research, National Marrow Donor Program® (NMDP)/Be The Match®